

International Journal of Ayurveda and Pharma Research

Research Article

THE MANAGEMENT OF PRIMARY DYSMENORRHOEA (*KASHTARTAVA*) - A PROSPECTIVE MULTICENTRIC OPEN OBSERVATIONAL STUDY

Ota Sarada^{1*}, Devi Kanchnara P², Kutty Madhavi P³, Kumari Krishna⁴, Kale Kiran V⁵, Bhatnagar Anu⁶, Ota Sushmita Priyadarshini⁷, Tomar Rinku⁸, Jain Seema⁹, M N Subhashree¹⁰, N Srikanth¹¹, Padhi M M¹², Dhiman K S¹³

*¹Research Officer (Ayu.)(Scientist-2), ¹¹Assistant Director (Ayu.), ¹²Deputy Director (Tech.), ¹³Director General, CCRAS, New Delhi, India.

²Research Officer (Ayu.) (Scientist-2), Dr. Achanta Lakshmipati Research Centre for Ayurveda, Tamil Nadu, India.

³Research Officer (Ayu.) (Scientist-4) (Retd.), National Research Institute for Panchakarma, Cheruthuruthy, Kerala.

⁴Research Officer (Ayu.) (Scientist-4), Ayurveda Regional Research Institute, Jammu, India.

⁵Research Officer (Ayu.) (Scientist-3), Ayurveda Mental Health Research Institute, Nagpur, Maharashtra, India.

⁶Research Officer (Ayu.) (Scientist-2), Ayurveda Central Research Institute, Jaipur, India.

⁷Research Officer (Ayu.), Ayurvedic Research Institute for Mother and Child Health Care, Kerala, India.

⁸Research Officer (Ayu.), National Institute of Ayurvedic Pharmaceutical Research, Punjab, India.

⁹Research Officer (Ayu.), Ayurveda Central Research Institute, New Delhi, India.

¹⁰Research Officer (Ayu.), National Ayurveda Dietetics Research Institute, Bangalore, Karnataka, India.

Received on: 29/06/2015	Revised on: 14/07/2015	Accepted on: 22/07/2015

ABSTRACT

Objective: To evaluate the clinical usefulness of *Rajahpravartini vati* in the management of primary dysmenorrhoea (*Kashtartava*) and changes in the quality of life of the subjects.

Study design: A multi-centric prospective single arm observational study.

Setting and participants: 359 subjects aged between 16 - 35 years suffering from painful menstruation at least for three consecutive regular menstrual cycles were included in the study.

Intervention: *Rajahpravartini Vati* a classical Ayurvedic formulation was administered 250 mg b.d. with lukewarm water for 90 days followed by subsequent 90 days without intervention.

Outcome measures: The management of menstrual pain assessing by 10 points Visual Analogue Scale and improvement in the quality of life using SF-36 (RAND) questionnaire.

Results: The mean VAS score of pain at baseline was 6.94 ± 1.98 , decreasing to 1.7 ± 2.22 at 90th day which further decreased and maintained to 1.24 ± 1.9 up to 180^{th} day. Associated symptoms like nausea, vomiting, constipation, giddiness, breast tenderness, diarrhea, headache and fainting were completely relieved. The improvements of quality of life in 8 domains viz. pain, general health, physical functioning, social functioning, emotional wellbeing, energy/fatigue, limitation due to physical health and emotional problems at the end of 90th day of intervention was also significant (p<0.001) in comparison to baseline. No adverse event occurred during the treatment period.

Conclusion: *Rajahpravartini Vati* has shown a positive role for the treatment of dysmenorrhoea and to improve the quality of life of the subjects.

KEYWORDS: Primary Dysmenorrhoea; *Kashtartava*; *Rajahpravartini Vati*; Single arm - multicentric - prospective-observational study.

INTRODUCTION

Dysmenorrhoea is a medical condition of pain during menstruation but more realistic definition includes cases of sufficient magnitude so as to incapitate daily activities.^[1] A pain which is of uterine origin and directly linked to menstruation but with no visible pelvic pathology is called Primary dysmenorrhoea. Pain reaches a maximum between ages of 18 and 24 years and thereafter diminishes. The pain is mainly felt in hypogastrium and is often referred to inner and front aspects of the thighs. During a severe attack the patient looks drawn and pale and may sweat; nausea and vomiting are common; there may be diarrhoea and rectal and bladder tenesmus.^[2]

As per Ayurvedic classics, pain occurred in the any part of the body due to aggravation of *Vata dosha* and the main two reasons for it are obstruction in the

passage (*Margavarodha*) or loss of body tissues (*Dhatukshaya*). In certain conditions or gynecological disorders (*Yonivyapad*) like *Vataj Rajodushti, Udavarta* or *Udavartini, Antarmukhi* and *Suchirmukhi Yonivyapad* pain occurred during menstruation. According to *Maharshi Charaka*, in *Udavartini yonivyapad*, menstrual blood is pushed in upward direction by the aggravated *Apana vayu* (the governing force of menstrual force) due to obstruction in its normal flow in *Pakwashaya* (pericolon and pelvic region). On the basis of the symptom 'immediate relief of pain following discharge of menstrual blood' mentioned by *Charaka*, it appears to be the nearer to primary or spasmodic dysmenorrhoea.^[3, 4]

Population surveys suggest a wide variation in prevalence rate of dysmenorrhoea from studies around the world including India reporting a range between 28% and 71.7%.^[5-9] It is reported in a study that Dysmenorrhoea is a common problem in India (79.67%) and most of them (37%) suffered regularly from dysmenorrhoea severity.^[10]

In conventional system, drug therapy includes Prostaglandin Synthetase Inhibitors for pain management. However, their use is contraindicated in women with GI ulcers, bronchial asthma. Side effects include nausea, vomiting, diarrhoea, abdominal pain, constipation, heart burn and dizziness. Other drugs include hormone therapy and calcium channel blockers. ^[11]

To regulate uterine contractions and uterine tone, many effective Ayurvedic regimens are described in Ayurvedic classics and various studies have also been conducted; but a proper statistical analysis and interpretation are not available. Appropriate and validated parameters are lacking for assessment of efficacy of the drugs in some of these studies and sample size was also less to draw a conclusion. Further, health related quality of life has not assessed in any study. ^[12-15]

Keeping this in view, this study was carried out on well known and safe classical Ayurvedic formulation *Rajahpravartini vati* that is being successfully prescribed by Ayurvedic physicians since centuries.

OBJECTIVES

The primary objective of this study was to establish the therapeutic usefulness of an Ayurvedic compound formulation- *Rajahpravartini Vati* in the management of primary dysmenorrhoea (DYS). The secondary objective was to assess the changes in the quality of life of the patients of DYS and to make ascertain the clinical safety of *Rajahpravartini Vati*.

MATERIAL AND METHODS

Study design

This was a multi-centric prospective observational study. The patients were recruited between March, 2011 and August, 2012 from 09 central and regional Institutes of Council for Research in Ayurvedic Sciences (CCRAS) viz. Ayurvedic Central Research Institute, Delhi, Nagpur and Jaipur; Ayurvedic Contraceptive Drug Research Institute, Ahmedabad; National Ayurvedic Dietetics Research Institute, Bengaluru; Dr. Achanta Laxmipati Research Centre for Ayurveda, Chennai; National Research Institute for Panchakarma, Cheruthuruthy; Ayurveda Regional Research Institute, Jammu and Ayurvedic Research Institute for Mother & Child health Care, Thiruvanantapuram.

The study was approved by the Institutional Ethics Committee of each participating centre and complied with the Declaration of Helsinki and existing GCP guidelines of the country. All eligible subjects were screened after signing the informed consent form to the approved protocol prior to their enrollment in the study. All Investigators were trained in the protocol before initiation of the trial. The study has also been registered in Clinical Trial Registry of India, CTRI/2015/01/005429.

Inclusion and Exclusion criteria

The women aged between 16 to 35 years suffering from painful menstruation for at least three consecutive regular menstrual cycles (21 -35 days) having normal bleeding were included in the study. Patients of secondary dysmenorrhoea, abnormal reproductive system, pelvic inflammatory disease or any serious systemic disorders likely to influence the menstrual cycle, history of malignancy, hypo and hyperthyroidism, diabetes mellitus, hypertension, women using IUD/oral contraceptive pills, and participating in any other interventional study were excluded from the study. Pregnant and lactating women were also excluded.

Study procedures

At screening visit, subject's demographic profile, medical history, family history particularly related to dysmenorrhoea, menstrual history, *Prakriti* (body constitution) and vital parameters were recorded. At each visit i.e.at baseline, 30th, 60th and 90th day (interventional period) study medication were dispensed and clinical assessment were performed. The clinical assessment and pain intensity also measured at 120th, 150th and 180th day (follow up period without intervention).

Grading System

The intensity of menstrual pain was measured in Visual Analogue Scale (VAS) using a 10 cm line represented the continuum of the opinion of the women on degree of pain. One end of the line '0' represented 'No pain', and another end '10' represented the 'worst pain possible'.

The scores received from the scale were classified into mild, moderate and severe as follows:^[16]

Mild menstrual pain	1-3 points	Menstruation is painful but seldom inhibits normal activity			
Moderate menstrual pain	4-7 points	Daily activity is affected			
Severe menstrual pain 8-10 points		Activity clearly inhibited with associated symptoms viz. headache,			
	_	fatigue, vomiting, diarrhoea			

Health related Quality of life (HRQoL) was recorded at baseline and end of the 90th day by using RAND 36 items Short Form health survey (SF-36) questionnaire. Safety lab assessments were also done at the end of the intervention period.

Patient compliance was monitored by keeping a regular follow up of the patients by personal contact, telephonic/ electronic communication. The investigators used to check the medicine packing for its exhaustion at each visit.

Study population

There was no procedure adopted for determination of sample size. However, a total of 368 patients were enrolled in the study.

Intervention

Rajahpravartini vati (Figure-1) an Ayurvedic classical formulation was prepared as per the standard operative procedures mentioned in Ayurvedic Pharmacopoeia of India (API) and was tested for quality & safety parameters *viz.* heavy metal, aflatoxin, microbials & pesticide residue which was within limit. It was administered in a dose of 250 mg twice a day with lukewarm water for 90 days followed by subsequent 90 days without intervention.

Outcome measures

The primary outcome measure was changes in intensity of menstrual pain was assessed at baseline and every follow up i.e. 30th, 60th, 90th 120th, 150th and 180th day by Visual Analogue Scale (VAS). The secondary outcome measure was HRQoL assessed at baseline and 90th day by using RAND (SF-36) questionnaire. It contains 36 items for assessment of eight health domains: physical functioning, social functioning, role limitations due to physical health, role limitations due to emotional health, vitality, mental health, bodily pain and general health perception and scores for each domain range from 0-100 with higher scores indicating better HRQoL.

Statistical analysis

Subjects who have taken the medicine at least in one follow up after the baseline were analyzed which included all patients with a baseline visit and at least one follow up visit. The data of last follow up visit was considered as the data of subsequent follow up visit up to the end of study period by 'last observation carry forward method (LOCF)' under modified intention-totreat analysis for missing data. The data of nine subjects was excluded from the analysis as they were reported at baseline only. Further, the data of those subjects who fulfilled the SF-36 (RAND) health survey questionnaire, both at baseline and end of the drug intervention period (90 days), was taken for analysis.

The obtained data were entered and analyzed using the SPSS ver.15.0. Descriptive statistics e.g. frequencies and percentages for categorical variables; means and standard deviations (SD) for continuous variables were used to describe the total study cohort. Pair wise comparison and within subject effects of outcome measures were done by using repeated measures ANNOVA. Paired t-test was carried out for assessing the difference in health status (SF-36 health survey) from baseline to 90th day and demonstrated in a spider figure'. In all the analysis, p-values <0.05 were considered significant and *p*-values of the pair wise comparison were Bonferroni adjusted. McNemar's Test was used to know improvement status of the outcome measures and the percentage of cure between the follow ups.

RESULTS

Total 477 subjects were screened according to the inclusion and exclusion criteria of the study protocol for participation in the study and a total of 368 subjects were recruited. All vital parameters and lab safety parameters were performed within one week of the study initiation. The flow of the subjects through the study is shown in Figure-1. This paper reflects the analysis of 359 subjects including 36 subjects who dropped out from the study.




Figure1: Showing flow of patients in the study

The base line characteristics of demographic information: the average age of the subjects was $22.0 \pm (5.40)$ years (range 21-25 years), majority of subjects (62.1%) were students, 82.7% were having education up to 10^{th} or above. The menstrual pattern (amount and duration of menstrual flow and interval of cycle)

was normal in all the subjects. 54.3% (n=159) subjects were having the family history of dysmenorrhoea. Majority of subjects 56.3% (n=202) were having *Pittaj-kaphaja Prakriti*. The more detailed socio-economic and other characteristics of the subjects at baseline are shown in Table-1.

Baseline population	n (%)	Mean ± SD
Total patients	359 (100)	
Age (in years)		
• Total	359 (100)	22.0 ± 5.40
• 16-20	177 (49.3)	
• 21-25	101 (28.13)	
Educational status		
• Illiterate	11 (3.1)	
Upto primary/middle	48 (13.4)	
• Upto 10 th /college or above	297 (82.7)	
Data not available	3 (0.8%)	
Marital status		
Married	91 (25.30)	
Unmarried	268 (74.70)	
Non-smoker & non-alcoholic	359 (100)	
Family history of Dysmenorrhoea	195 (54.3)	
Body weight (in kg)		49.14 ± 10.01
Height (in cm)		154.33 ± 5.60
BMI (kg/m ²)		20.63 ± 4.06
Body vitals		
Pulse rate		74.1 ± 5.4
Respiration rate		17.0 ± 1.9
Blood pressure (in mm Hg)		
• Systolic		109.1 ± 8.3
• Diastolic		71.71 ± 7.7
Prakriti (Predominant)		
• Pittaja-kaphaja	202 (56.3)	
• Vata-pittaja	87 (24.2)	


Menstrual history		
• Age of menarche		13.51 ± 1.18
Duration of menstrual flow		4.48 ± 1.1
 Amount of bleeding/day (in no. pads) 		2.41 ± 0.74
Length of menstrual cycle (in days)		28.95 ± 3.3
Outcome measures:		
Menstrual pain (in VAS)		
• Abdomen	359(100)	
Low back	312 (86.9)	
Lower limbs	272(78.8)	
Associated symptoms		
Nausea	119 (33.1)	
Vomiting	76 (21.2)	
Constipation	61 (17)	
• Giddiness	88 (24.5)	
SF-36 (RAND) score		760,00
Physical functioning		76.9 ± 26.8 57.56 ± 42.84
Role Limitations due to physical health		57.50 ± 42.04 65.83 ± 41.01
 Limitations due to emotional problem 		61.3 ± 19.8
Energy/Fatigue		69.45 ± 18.01
Emotional well being		73.5 ± 22.2
Social Functioning		61.3 ± 21.4
• Pain		0110 - 2111
Lab safety parameters		
Hemoglobin (g/dl)		11.34 ± 1.6
• Blood urea (mg/dl)		17.6 ± 5.20
• Serum creatinine mg/dl)		0.70 ± 0.5
Serum Glutamic Oxaloacetic Transaminase (SGOT) (IU/L)		20 ± 6.3
Serum Glutamic Pyruvic Transaminase (SGPT) (IU/L)		18.6 ± 10.0
Serum Bilirubin Total (mg/dl)	a	0.53 ± 0.23


ITT – Intention to treat; n - Number of subjects; SD - Standard Deviation

Data are prese<mark>nte</mark>d in mean± (SD) and number (%)

Effects on symptoms and intensity of disease

There was decreasing trend of mean VAS scores of pain in abdomen during menstrual cycle at each visit for the total study population. The mean VAS score at baseline was 6.94 SD (1.985), decreasing to 4.33 SD (2.63) at 30th day, 2.74 SD (2.47) at 60th day and 1.74 SD (2.22) at 90th day and further decreased and maintained to 1.24 SD (1.90) up to 180th day. The within group change from baseline was significant at all visits (p<0.001) (Wilcoxon signed rank test). The decrease from baseline at 90th day was 5.20 (95%Cl 4.78-5.62) and this was maintained during the post treatment period 5.68 (95%Cl 5.25-6.11) up to 180th day (Figure-2).





The subjects also got relief on the associated symptoms like nausea, vomiting, constipation, giddiness, breast tenderness, diarrhea, headache and fainting. The status of patients as relieved/ static/ worse at the end of the intervention and end of the observation period by using McNemar test is presented at Table-2. The data is showing statistically significant changes (p<0.001).


Variables	After intervention period (90 th day) (n,%)				End of the period without intervention (n, %)					
	Relieved	Static	Worse	Chi square	P value	Relieved	Static	Worse	Chi square	P value
Pain in abdomen	137 (38.16)	222 (61.83)	0	135.08	< 0.01	207 (57.66)	152 (42.33)	0	1.59	0.21
Low Backache	185 (51.67)	167 (46.64)	6 (1.6)	165.88	< 0.01	223 (62.11)	133 (37.04)	3 (0.8)	0.09	0.76
Pain in lower limbs	199 (55.43)	155 (43.17)	5 (.01%)	182.59	<0.01	220 (61.28)	133 (37.04)	6 (1.67)	0.108	0.74

Table 2: Overall effect of the trial drug on primary outcome measures

Static (No change in score) depicts patients who were either asymptomatic or same as baseline. In McNemar test, only discordant cells are used for data analysis. Accordingly relieved (Complete reduction in score) and worsened (Increase in score from baseline) patients have been considered for analysis.

Changes in health related quality of life

The findings of this study shows that the score received on the various domains of SF-36 scales were improved at the end of 90th day and effect seen were also significant (p<0.001) (Figure-3).





All subjects tolerated the treatment well. None of the subjects developed any adverse drug reaction. There was no remarkable change in any of the safety lab parameters.

DISCUSSION

In this study, the effect of *Rajahpravartini vati* (Figure-4) on primary dysmenorrhoea has been evaluated. There was significant reduction in the menstrual pain and also improvement in the quality of life (physical as well as psychological) of the patients. The reduction of the pain was also stable during the follow up period without administering trial intervention. It proves the long lasting effect of the regimen. Some associated symptoms of primary dysmenorrhoea like nausea, vomiting, giddiness, constipation, diarrhea, fainting reported at baseline

were almost completely reduced just after $30^{\mbox{th}}$ day of the treatment.



Figure 4: Rajahpravartini vati (tablet)

In Avurvedic classics, drugs having carminative, laxative, anti-spasmodic properties are indicated in dysmenorrhoea and *Rajahpravartini vati*^[17,18] seems to have all properties which help to cure dysmenorrhea. It contains purified *Hingu* (*Ferula* asafetida H.Kar.st), purified Kaseesa (Ferus sulphate), purified *Tankana* (borax) and Pulp of *Aloe vera* Linn. in equal quantity which is processed in Juice of Aloe vera. Hingu is reported to have antispasmodic activity. ^[19] In one study it was concluded that Aloe vera seems to reduce the severity of dysmenorrhea and can be a replacement to non-steroid anti-inflammatory tablets. ^[20] The mean age of the subjects was 22 years which also validate theory of the age of more prevalence of primary dysmenorrhoea. No adverse effects were reported during study period and no abnormalities were also found in the renal or liver functions. So, this Ayurvedic regimen appears clinically safe. Further, though it is not statistically significant as the patients were instructed not to try for pregnancy during the study period, it is observed that three women having the history of primary infertility got pregnancy during the treatment period. Further, study in this regard is suggested to prove its efficacy on infertility.

There were some limitations in this study. Though the consumption of analgesic was reduced/ not required during the study period but the specific data could not be reported due to inadequate information from the subjects. Further, no comparator group was taken to compare the efficacy of trial drug and prostaglandin was not assessed to know the mechanism of the action of the drug. In future study, these points may be taken into account.

CONCLUSION

This study has provided a clear cut support for clinical use of *Rajahpravartini vati* to treat primary dysmenorrhoea and clinically meaningful improvement of quality of life of the dysmenorrhoic women. However, because of the open label and noncomparative nature of the present study, the findings may further be corroborated through a randomized, controlled study.

SOURCE OF FUNDING

The authors are thankful to Central Council for Research in Ayurvedic sciences (CCRAS), New Delhi for providing the financial assistance to conduct this multicentric study.

ACKNOWLEDGEMENT

The authors are thankful to all the patients for their participation in the study all the Incharges and staff of participating centers for providing logistic and technical support during data collection. The authors are also thankful to Sh. R. K. Rana, Statistical Officer, and Dr. Richa Singhal, Statistical Assistant, CCRAS for data analysis and Dr. Arun Bhadula, SRF, CCRAS for technical assistance.

CONTRIBUTION OF AUTHORS

All authors are involved in drafting the manuscript or revising critically the important components and approved the final version to be submitted for publication.

Declaration of conflicts of interests: All authors declared no conflicts of interest with respect to the research, authorship and publication of this article.

REFERENCES:

- Dutta D C, Text book of Gynaecology, 5th Edition 2009; New Delhi, New Central Book Agency (P) Ltd.; Chapter-13; p 174-175.
- Pratap Kumar & Narendra Malhotra, Jeffcoate's Principles of Gyanaecology, New Delhi, Jaypee Brothers Medical Publishers (P) Ltd. 7th Edition; 2008; Chapter - 39; p. 617-618.
- 3. Sharma RK, Bhagwan Dash; Agnivesha's Charaka Samhita (Text with English Translation and Critical exposition based on Chakrapani Datta's Ayurvedadikpika); 2010; Vol. V (Chikitsasthana Chapter XXX), Varanasi; Chaukhamba Sanskrit Series Office; p 135-136.
- Premvati Tiwari; Ayurvediya Prasutitantra Evam Stree roga, Part-II Streeroga; Chapter – 1; 2nd Edition; 2008; Varanasi, Chaukhamba Orientalia; p. 33-35.
- 5. Alaettin Unsal, *et al:* Prevalence of dysmenorrhoea and its effect on quality of life among a group of female University students. Upsala Journal of Medical Sciences.2010; 115; 138-145.
- 6. Latthe P, *et al*: WHO systematic review of prevalence of chronic pelvic pain: A neglected reproductive health morbidity. BMC public health 2006; 6:177. (http://www.biomedcentral.com/1471-2458/6/177)
- 7. Atchuta Kameswar Rao Avasarala and Saibharghavi Panchangam: Dysmenorrhoea in Different Settings: Are the Rural and Urban Adolescent Girls Perceiving and Managing the Dysmenorrhoea Problem Differently? Indian Journal of Community Med;2008 Oct;33(4): 246-249.
- 8. Neamat A. Abd El-Hameed , Maher S. Mohamed , Nadia H. Ahmed and Eman R. Ahmed; Assessment of Dysmenorrhea and Menstrual Hygiene Practices among Adolescent Girls in Some Nursing School at EL-Minia Governorate,Egypt,Journal of American Science, 2011;7(9); 216-223.
- 9. Anandha Lakshmi S. et al, Prevalence of Premenstrual Syndrome and Dysmenorrhoea among Female Medical Students and its Association with College Absenteeism, International Journal of Biological & Medical Research, 2011; 2(4): 1011-1016.

- 10. Anil K Agarwal and Anju Agarwal A Study of Dysmenorrhea during Menstruation in Adolescent Girls. Indian J Community Med.; Jan 2010 35(1); 159-16.
- Pratap Kumar & Narendra Malhotra; Jeffcoate's Principles of Gyanaecology; 7th Edition; 2008; New Delhi, Jaypee Brothers Medical Publishers (P) Ltd.7th Edition; 2008;Chapter - 39; p. 619-622.
- 12. Haritalakshmi, B. Vijayalakshmi, B. Subbalaxmi; Clinical study of Udavartini (Dysmenorrhea) Yonivyapath with oral Administration of Jeerakadimodaka and Rasnaditaila Matravasti; International Journal for Ayurveda and Pharma Research; 2013; 1(3): 66-71.
- 13. Shabnam Jahan, N. Sujahtha, Neelam, Role of Uttara Vasti with Trivrit and Lasuna oil in the management of Primary dysmennorhoea; AYU; Apr-Jun 2010; Vol. 31(2); 228-231.
- 14. Dhiman Kamini, *et al*: Chaturbeeja in Primary dysmenorrhea (Kashtartava); An observational study Chaturbeeja, Journal of Pharmaceutical and Scientific Innovation 1(3); May – June 2012; 27-31
- 15. Shabnam Omidvar, *et al*, Effect of fennel on pain intensity in dysmenorrhoea: A placebo

Cite this article as:

Ota Sarada, Devi Kanchnara P, Kutty Madhavi P, Kumari Krishna, Kale Kiran V, Bhatnagar Anu, Ota Sushmita Priyadarshini, Tomar Rinku, Jain Seema, M N Subhashree, N Srikanth, Padhi M M, Dhiman K S. The Management of Primary Dysmenorrhoea (Kashtartava) - A Prospective Multicentric Open Observational Study. International Journal of Ayurveda and Pharma Research. 2015;3(7):7-14.

Source of support: Nil, Conflict of interest: None Declared

controlled trial; AYU; 2012 Apr-Jun; 33(2): 311-313.

- 16. Alaettin Unsal, *et al*, Prevalence of dysmenorrhoea and its effect on quality of life among a group of female university student, Upasala Journal of Medical Sciences, May 2010; 115(2); 138-145.
- 17. Ambika Datta Shastri; Govinddas Sen virachita Bhaisajya Ratnavali; Chaukhamba Sanskrit series,1996; Prakarana 67; verse 58-60; p. 726.
- The Ayurvedic Formulary of India (AFI); Part –I; 2nd Revised English Edition 2003; Delhi; The Controller of Publications Civil Lines; Section-12; 12:25; p.192.
- 19. Fatehi M, Farifteh F, Fatehi-Hassanabad Z. Antispasmodic and hypotensive effects of Ferula asfoetida gum extract; Journal of Ethnopharmacology 91 (2004): 321-324.
- 20. Somaie Kazaeeian, Ali Navidian, Shain dokht navabi rigi; Evaluation Effects of oral Aloe vera gel on the intensity of primary dysmenorrhea; Medical Surgical Nursing Journal; 3.2012;Volume 1 Number 1: 35-40.

*Address for correspondence Dr. Sarada Ota

Research Officer (S-2) (Ayu.) Central Council for Research in Ayurvedic Sciences (CCRAS) Hqrs., New Delhi, India. Email: sarada_ota@yahoo.com Mobile: +919810425662 Tele-Fax: (+91-11)-28525410